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Abstract The cellular prion protein, encoded by the gene
Prnp, has been reported to be a receptor of β-amyloid.
Their interaction is mandatory for neurotoxic effects of β-
amyloid oligomers. In this study, we aimed to explore
whether the cellular prion protein participates in the
spreading of α-synuclein. Results demonstrate that Prnp
expression is not mandatory for α-synuclein spreading.
However, although the pathological spreading of α-
synuclein can take place in the absence of Prnp, α-
synuclein expanded faster in PrPC-overexpressing mice.
In addition, α-synuclein binds strongly on PrPC-express-
ing cells, suggesting a role in modulating the effect of α-
synuclein fibrils.
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Introduction
T h e c e l l u l a r p r i o n p r o t e i n ( P r P C ) , a
glycosylphosphatidylinositol (GPI)-anchored protein, partici-
pates in several neural functions [1–3]. Relevantly, one of the
most recently described functions of the protein points to PrPC
is as a receptor for β-amyloid (Aβ) [4]. Indeed, today it is well
established that Aβ oligomers can bind with great affinity to
PrPC [5, 6, 4, 7, 8] and to recombinant prion protein (e.g. [9,
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10]). After binding, it was also proposed, although with some
controversy [9, 11–13], that this interaction plays a crucial role
in neurotoxic effects of Aβ oligomers such as inhibition of
long-term potentiation (LTP), neuronal cell death and memory
impairment in some mouse models of Alzheimer’s disease
[14, 6, 4, 15–17]. Amyloid aggregates are present in many
neurodegenerative diseases, and their formation occurs in a
multistep process including the misfolding of healthy soluble
proteins and their association into amyloid fibrils that form
cell inclusions. In fact, among other aggregates (e.g. SOD1,
CEPB3, TDP-43, etc.), those of Tau and α-synuclein, charac-
teristic of tauopathies/Alzheimer’s disease and Parkinson’s
disease, respectively, showed cell-to-cell transport in healthy
cells through their uptake of misfolded polymers, which can
propagate and spread throughout the neural parenchyma
[18–23].
α-Synuclein is a key player in the pathogenesis of
synucleinopathies, including Parkinson’s disease, dementia
with Lewy bodies and multiple system atrophy [24].
Transmission of synthetic α-synuclein aggregates has been
demonstrated in several cellular and animal models (see
[25–27] for reviews). Several groups have reported that α-
synuclein shows prion-like propagation in wild-type mice
[28–30]. However, the basis of the spreading process remains
poorly understood although cell-to-cell transport via exocyto-
sis has been suggested [31–33]. For this reason, PrPC is pro-
posed as an Aβ receptor (see above), and in this study, we
aimed to explore whether PrPC is involved in the propagation
and spreading of α-synuclein. Results demonstrated that α-
synuclein could propagate and spread in mice lacking or over-
expressing Prnp, including wild-type mice. However, in-
creased quantities of p-α-synuclein can be seen in the motor
cortex of PrPC-overexpressing mice as compared to Prnp+/+
and Prnp0/0 mice. In addition, in vitro experiments also cor-
roborated that although not required to trigger α-synuclein
transport, Prnp overexpression enhances transported α-synu-
clein. In fact, α-synuclein binds strongly to Prnp-transfected
HEK293 cells in contrast to mock-transfected ones.
Moreover, the absence of the charged cluster (CC) domain
of PrPC impairs α-synuclein binding in transfected cells. In
conclusion, our results point to a non-mandatory but relevant
role of Prnp in α-synuclein transport.
Material and Methods
Mouse Strains and Genotyping Adult male C57Bl6/129sv-
Prnp0/0 (B6129 PrnpZrchl/Zrchl Zurich I) mice were purchased
from the European Mouse Mutant Archive (EMMA,
Monterotondo, Italy) [34]. We backcrossed to C57BL/6 J for
at least 8–9 generations to obtain 6–7% of 129 microsatellites
in B6.129 Prnp0/0 and control littermates B6.129 Prnp+/+
[35]. These Prnp0/0 and Prnp+/+ mice were used in the present
study. Specific primers for Prnp genotyping were designed in
our laboratory based on the original P3 and P10 primers as
described [34]: neo: 5′-gccttctatcgccttcttgac-3′; 3′ NCnew: 5′-
g c t a c a g g t g g a t a a c c c c t c - 3 ′ a n d P 1 0 n e w : 5 ′ -
cataatcagtggaacaagccc-3’ [36]. Forty cycling conditions were
45″ 95 °C; 45″ 62 °C; 1′ 72 °C, followed by a final extension
at 72 °C for 5 min. Prnp-overexpressing mice (Tga20) were
purchased from EMMA (Monterotondo, Italy). They were
generated as described by Marek et al. [37] and backcrossed
in our lab with B6.129 Prnp0/0 mice for seven generations
[36]. The backcrossed mice were used in the study. For
Tga20 mice, the transgene was detected using primers specific
to the Tg20 allele 5′-caaccgacgtgaagcattctgccta-3′ and 5′-
cctgggactccttctggtaccgggtgacgc-3′ as indicated [38]. The
Ethics Committee on Animal Experimentation (CEEA) of
the University of Barcelona approved all procedures described
in this study. All housing, breeding and procedures were per-
formed under the guidelines and protocols #276/16 and #141/
15 of CEEA.
Preparation of Recombinant α-Synuclein Monomer and
Fibrils Mouse and human α-synuclein complementary
DNAs (cDNAs) in bacterial expression plasmid pRK172
were used. α-Synuclein was expressed in Escherichia coli
BL21 (DE3) cells and purified using boiling, Q-sepharose
ion exchange chromatography and ammonium sulphate
precipitation. Purified α-synuclein protein was dialyzed
against 30 mM Tris–HCl, pH 7.5, and cleared using ul-
tracentrifugation at 113,000g for 20 min. Protein concen-
tration was determined with reverse phase HPLC. Proteins
were loaded on an Aquapore RP-300 column (Brownlee)
Perkin Elmer (Waltham, MA, USA) (equilibrated in
0.09% trifluoroacetic acid with a linear gradient of aceto-
nitrile 0 to 50% at a flow rate of 1 ml/min). Purified
mouse α-synuclein monomer (7 mg/ml) in 30 mM Tris–
HCl, pH 7.5, containing 0.1% NaN3, was incubated at
37 °C in a shaking incubator at 200 rpm for 72 h. α-
Synuclein fibrils were pelleted by spinning at 113,000g
for 20 min and then suspended in PBS. α-Synuclein fi-
brils were sonicated with an ultrasonic homogenizer (VP-
5S) Taitec (Nishikata, Japan) (at high power for 10 cycles
(30 s on, 30 s off at 10 °C) before use. Aliquots of son-
icated and non-sonicated fibrils were processed for trans-
mission electron microscope (TEM) analysis and negative
staining (Supplementary Fig. 1). In parallel, SDS-PAGE
and western blot revealed the presence of a relevant
17 KDa and upper bands >35 KDa after sonication typical
of protofibril preparations (Supplementary Fig. 1). To de-
termine the concentration, fibrils were dissolved in 7 M
guanidine hydrochloride and analysed with RP-HPLC as
described above. Generated fibrils were tested to insure
that they were endotoxin-free to avoid unwanted effects
as described [39].
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Transmission Electron Microscopy Procedures Fibril solu-
tions were fixed to carbon-forward-coated copper supports,
and negative staining was performed using a 2% PTA-based
(phosphotungstic acid) stain (pH 7.4), after which samples
were placed in silica-based desiccant for a minimum of 2 h.
Finally, we proceeded to TEM observation using a Leica elec-
tron microscope (Wetzlar, Germany) at SCT, University of
Barcelona, Barcelona, Spain (Supplementary Fig. 1).
Stereotaxic Surgery Five- to 6-month-old mice were
anaesthetised with 50 mg/kg pentobarbital sodium and then
were unilaterally injected with 5 μg (1 μg/μL solution) of
recombinan t mouse sonica ted α - synuc le in in to
postcommissural striatum (A-P 3.5 mm; M-L: 3.5 mm; D-V
−0.9 mm from Bregma) at a rate of 0.1 μL/min. In parallel,
some mice (n = 3) were sham-operated (Supplementary
Fig. 1d). In these mice, the skull was opened and a glass
pipette was placed in the abovementioned coordinates. After
10 min, the pipette was removed and the skin sutured. Sham-
operated and fibril-injected mice were anaesthetised 45 days
later with isofluorane and perfused with 4% buffered parafor-
maldehyde (pH 7.3). For immunohistochemistry, free-floating
sections were rinsed in 0.1 M PBS, and endogenous peroxi-
dase activity was blocked by incubation in 3%H2O2 and 10%
methanol dissolved in 0.1 M PBS. After extensive rinsing,
sections were incubated in 0.1 M PBS containing 0.2% gela-
tin, 10% normal serum, 0.2% glycine and 0.2% Triton X-100
for 1 h at room temperature. Afterwards, the sections were
incubated for 24 h at 4 °C with the primary antibody: p-α-
synuclein (p129S, clone 81A (cat. ab184674), 1:2000 diluted,
Abcam, Cambridge, UK). After that, the sections were incu-
bated with secondary biotinylated antibodies (2 h, 1:200 di-
luted) and streptavidin-horseradish peroxidase complex (2 h,
1:400 diluted). Peroxidase activity was revealed with 0.025%
diaminobenzidine (DAB) and 0.003% hydrogen peroxide.
After rinsing, the sections were mounted onto slides,
dehydrated and coverslipped with Eukitt™ (Merck,
Darmstadt, Germany). Samples were photodocumented using
an Olympus (Hamburg, Germany) BX61 microscope
equipped with a cooled digital DP72L camera. For quantifi-
cation of Lewy body-like (LBL) p-α-synuclein-positive ag-
gregates in motor cortex, equivalent sections at the level of the
frontal cortex between Bregma 0 and 1 were selected (2–3
sections per mouse), and the total number of neuronal aggre-
gates (LBL) of p-α-synuclein in layer V (300 μm w × 150 μm
h box) was counted using a ×40 objective (oil immersion
Zeiss, N.A. 0.85). Statistical analysis of the obtained data
was performed with Bonferroni post hoc test (multiple com-
parison test) using GraphPad Prism 6 (Mac OsX, Graphpad).
Data are presented as mean ± standard error of the mean
(SEM). Differences between groups were considered statisti-
cally significant at **P < 0.01 and *P < 0.05.
Microfluidic Devices Two different devices were used in an
optimized modification of our previous design of large dual-
chamber, open neuronal co-culture and of designs reported by
Taylor et al. [40]. The open microfluidic device consists of
two main open chambers interconnected by 100
microchannels. The large chamber areas (9 mm × 16 mm) fa-
cilitate effective cell culture and easy handling. The small
cross-section areas of microchannels (3 μm × 10 μm or
10 μm × 10 μm) restrict the crossing of cortical neuron cell
bodies but permit the passage of neuronal processes. The
microfluidic device was made of poly(dimethylsiloxane)
(PDMS) using standard photolithography and soft
lithography.
Primary Embryonic Neuronal Cultures E15.5 mouse em-
bryo brains were dissected and washed in ice-cold 0.1 M
phosphate-buffered saline (PBS) containing 6.5 mg/ml glu-
cose. The meninges were removed and the cortices isolated.
Tissue pieces were trypsinized for 15 min at 37 °C. After the
addition of horse serum and centrifugation, cells were disso-
ciated by trituration in 0.1 M PBS containing 0.025% DNAse
with a fire-polished pipette. Dissociated cells were plated at
~10,000 cells/mm2 on one of the two reservoirs of
microfluidic devices (A and B in Fig. 3) coated with poly-D-
lysine (Sigma, Madrid, Spain). The culture medium was
Neurobasal supplemented with 2 mM glutamine, 6.5 mg/ml
glucose, antibiotics and B27 (Invitrogen-Life Technologies,
Barcelona, Spain). After 72 h, 5 μM AraC (cytosine β-D-
arabinofuranoside hydrochloride, Sigma) was added for 48 h
to inhibit the growth of dividing non-neuronal cells. For char-
acterization, cultures were immunostained using anti-glial fi-
brillary acidic protein (GFAP, cat. z0334; 1:500, Sigma), basic
helix-loop-helix (bHLH) transcription factor olig2 (cat.
AB9610, 1:200; Abcam) and class III β-tubulin (TUJ1, cat.
801201, 1:3000; Biolegend, CA, USA). Cultures contained
up to 90% neurons (TUJ1-positive) and were used after 5–
7 days in vitro. In parallel, some cultures were stained with
Fluo4-AM (1 mg/ml, F14201, Invitrogen-Life Technologies)
to confirm axonal interconnection between reservoirs prior to
their processing.
Plasmids and Construction of PrPC-Deleted FormsMouse
PrPC-encoding plasmid (pcDNA 3.1 backbone) and PrPC-
IRES-GFP were provided by D. A. Harris (Boston
University School of Medicine, Boston, MA, USA) and
PrPC-truncated form ΔF35 by A. Aguzzi (University
Hospital Zürich, Institute for Neuropathology, Switzerland).
To generate deletion constructsΔCD,ΔCC,ΔHR andΔCR,
the PrPC-encoding plasmid was used as a template for inverse
PCRs, and the inserts obtained were fused. Briefly, a primer
set was designed for each construct in order to amplify the
entire plasmid, except for the region of Prnp to be deleted, i.e.
regions 95–133, 95–110, 112–133 and 105–125 for ΔCD,
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ΔCC, ΔHR and ΔCR, respectively. Primers (Ecogen) were
as follows: CD (F: 5′-AGCAGGCCCATGATCCATTTTG-3′,
R: 5′-ATGGGTACCCCCTCCTTGGC-3′); CC (F: 5′-GTGG
CAGGGGCTGCGGCAG-3′, R: 5′-ATGGGTACCCCCTC
CTTGGCC-3′); HR (F: 5′-AGCAGGCCCATGATCCATTT
TG-3′, R: 5′-TGCCACATGCTTGAGGTTGG-3′); CR (F:
5 ′ -TACATGCTGGGGAGCGCC-3 ′ , R : 5 ′ -TTTT
GGTTTGCTGGGCTTGTTC-3′). After amplification
(Accuprime Taq Polymerase™, Invitrogen), the blunt ends
of the amplimers were phosphorylated using the T4 kinase
reaction (Invitrogen) and then religated (Fast-Link Ligase™,
Epicentre Biotech.). An aliquot of each ligation reaction was
electroporated into Escherichia coliDH5α, and transformants
were selected for ampicillin resistance. Twenty-five candi-
dates were selected and screened with sequence analysis
(Terminator Big Dye™ v3.1, Applied Biosystems).
Cell Culture and Transfection HEK293 cells (ATCC CRL-
1573™, American Type Culture Collection, MD, USA) were
maintained in Dulbecco’s modified eagle medium (DMEM,
Invitrogen-Life Technologies), 10% foetal bovine serum
(FBS, Invitrogen-Life Technologies) and 1% penicillin/
streptomycin (Invitrogen-Life Technologies) in 75 cm2 cul-
ture bottles in a 5% CO2 atmosphere at 37 °C. One day before
transfection, cells were cultured in DMEM supplemented with
10% FBS and without antibiotics, on poly-D-lysine (Sigma)
coated plates. Transfection was performed using
Lipofectamine Plus (Invitrogen-Life Technologies), according
to the manufacturer’s instructions as indicated [41].
Caspase-3 Activity Twenty-four hours after transfection,
cells were scraped and lysed for 20 min on ice in cold lysis
buffer (50 mMHepes pH 7.5, 150 mMNaCl, 1.5 mMMgCl2,
1 mM EGTA pH 8, 10% glycerol, 1% Triton X-100) contain-
ing 1x protease inhibitor cocktail and phosphatase inhibitors.
Lysates were centrifuged at 12000g for 5 min at 4 °C and
supernatants were collected. Protein concentration was deter-
mined using a BCA protein assay kit (Pierce). The caspase-3
activity assay, with Ac-Asp-Glu-Val-Asp-7-amino-4-
trifluoromethylcoumarin (Ac-DEVD-AFC, Sigma) as a sub-
strate, was performed as previously described [42].
Immunocytochemical Procedures One day before transfec-
tion, counted HEK293 cells were seeded onto poly-D-lysine
(0.01 μg/μl) coated glass coverslips (12 mm Ø). Three days
post-transfection, mouse α-synuclein (1 μg/ml medium) was
added to the culture media. Treatment with α-synuclein was
maintained for 3 days. Cells were fixed in 4% buffered para-
formaldehyde (Sigma) and then permeabilized with 0.1%
Triton X-100 (Sigma) in 0.1 M PBS. A similar fixation pro-
cedure was used for microfluidic devices (see [43] for details).
After fixation, and extensive rinsing with 0.1 M PBS, cultures
were blocked with 10% FBS in 0.1 M PBS prior to incubation
with primary antibodies. Neurons were identified using a class
III β-tubulin antibody (1:3000 diluted; Biolegend). PrPC was
detected using anti-mouse 6H4 (1:500, Prionics; Schlieren,
Switzerland), which recognizes the sequence DYEDRYYRE
of the prion protein (human PrPC: aa 144–152), α-synuclein
(1:500 diluted; Cell Signalling) and p-α-synuclein (mouse and
human) (p129S/81A; 1:400 diluted; Abcam). After incubation
with primary antibodies, cells were incubated with the perti-
nent Alexa Fluor-tagged secondary antibodies (Alexa-488
goat anti-mouse or Alexa-568 goat anti-rabbit) (Invitrogen-
Life Technologies). Finally, cells were stained with 0.1 μM
DAPI (Sigma) diluted in 0.1 M PBS, mounted on Mowiol™
(Calbiochem, San Diego, CA, USA) and viewed using an
Olympus BX61 fluorescence microscope.
Western Immunoblot Samples were homogenized in 10%
wt/vol of 50 mM Tris–HCl, pH 7.4/150 mM NaCl/0.5%
Triton X-100/0.5% Nonidet P-40, and a mixture of protease
inhibitor cocktail (Roche, Basel, Switzerland) and phospha-
tase inhibitors (10 mM tetra-sodium pyrophosphate, 200 μM
sodium orthovanadate and 10 mM sodium fluoride). After
this, samples were centrifuged at 15,000g for 20 min at
4 °C. The resulting supernatant was normalized for protein
content using BCA kit (Thermo Scientific Pierce, Paisley,
UK). Cell extracts were boiled at 100 °C for 10 min, followed
by 6% SDS electrophoresis and were then electrotransferred
to nitrocellulose membranes for 1 h at 4 °C. Membranes were
then blocked with 5% fat milk in 0.1 M Tris-buffered saline
(pH 7.4) for 1 h and incubated overnight in 0.5% blocking
solution containing primary antibodies. After incubation with
peroxidase-tagged secondary antibodies (1:2000 diluted,
Sigma), membranes were revealed with an ECL-plus chemi-
luminescence western blot kit (Amershan-Pharmacia Biotech,
Piscataway, NJ, USA). In some experiments, peroxidase ac-
tivity was revealed using a high sensitivity ECL-
chemiluminescence kit (QuantaRed™, Thermo Scientific).
In our experiments, each nitrocellulose membrane was used
to detectα-synuclein (1:1000; Cell Signalling), p-α-synuclein
(1:1000, p129S/81A; Abcam), β-actin (1:20,000; Sigma), β-
tubulin (1:10,000; Sigma) and class III β-tubulin antibody
(1:5000; Biolegend).
Densitometry and Statistical Processing For quantification,
developed films were scanned at 2400 × 2400 dpi (i800
MICROTEK high quality film scanner), and the densitometric
analysis was performed using the Quantity One Image
Software Analysis (Biorad, Barcelona, Spain). Statistical anal-
ysis of the obtained data was performed with Bonferroni post
hoc test (Multiple comparison test) using GraphPad Prism 6
(Mac OsX, Grahpad). Data are presented as mean ± SEM.
Differences between groups were considered statistically sig-
nificant at *P < 0.05.
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Results
α-Synuclein Transport in Prnp+/+, Prnp0/0 and Tga20
Mice Adult Prnp+/+, of recombinant endotoxin-free mouse
α-synuclein (Fig. 1) in the postcommissural striatum, and
the presence of phosphorylated α-synuclein (p-α-synuclein,
p129S/81A–positive), were analysed 45 days later. Both
sham- and non-operated mice presented the described pattern
of p-α-synuclein in the adult mouse telencephalon
(Supplementary Fig. 1, [44]). The antibody p129S/81A
showed minor cross-reactivity with phosphorylated
Neurofilament L. Indeed, several telencephalic regions
showed background staining including the cingulate and pa-
rietal neocortex, hippocampus, striatum and some telence-
phalic axonal tracts (e.g. mamillothalamic tract)
(Supplementary Fig. 1) [44]. However, aggregated forms of
p-α-synuclein such as Lewy body-like (LBL) or Lewy
neurite-like (LNL) forms were never observed after
immunohistochemistry using the p129S/81A antibody in the
telencephalon of non-operated and sham-operated mice, only
appearing in the telecephalon after α-synuclein fibril injec-
tions (Supplementary Fig. 1). High magnification of LBL ob-
served in the neocortex and amygdala 45 days after mouse α-
synuclein striatal injections can be seen in Supplementary
Fig. 1f, g. As observed, these aggregates were clearly identi-
fiable over the background even using Ni-DAB development.
As indicated, the mice were processed after 45 days post-
injection (Prnp+/+ (n = 6); Prnp0/0 (n = 6) and Tga20 (n = 7))
in order to determine whether the regional distribution of p-α-
synuclein was similar in the different Prnp genotypes (Figs. 1
and 2, Supplementary Fig. 1). Injection of mouse α-synuclein
sonicated fibrils into postcommissural striatum induced p-α-
synuclein pathology bilaterally throughout the brain, includ-
ing striatum, amygdala, stria terminalis, substantia nigra and
neocortex (Figs. 1 and 2, Supplementary Fig. 1). The anatom-
ical and cellular distribution of p-α-synuclein aggregates was
Fig. 1 p-α-Synuclein pathology
in the telencephalon of Prnp0/0,
Prnp+/+ and Tga20 mice injected
with mouse α-synuclein fibrils in
the postcommissural striatum. a-c
Schemes illustrating the location
of p-α-synuclein deposits
(asterisks) shown in panels (d–o).
d-o High power
photomicrographs showing p-α-
synuclein labelling in the striatum
(d–f); neocortical layer V (g–i);
amygdala (j–l) and S. nigra (m–o)
of Prnp0/0 (d, g, j,m), Prnp+/+ (e,
h, k, n) and Tga20 (f, i, l, o) mice.
Note the relevant accumulation of
p-α-synuclein labelling in
intracellular deposits of
retrograde-labelled projecting
neurons. Scale bar: d = 100 μm
pertains to e–o
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observed in Prnp+/+, Prnp0/0 and Tga20 mice, as previously
reported for wild-type mice in another study using similar α-
synuclein fibrils and protocols [30]. At the cellular level, p-α-
synuclein was mainly located in neurites and the neuronal
perikaryon (as thick LBL or LNL aggregates) (Figs. 1 and 2,
Supplementary Fig. 1e, f). At these post-inoculation times,
p-α-synuclein labelling was observed bilaterally in the stria-
tum, substantia nigra, amygdala, and entorhinal cortex and,
ipsilaterally, in the motor cortex. However, although α-
synuclein pathology was observed in the absence of Prnp,
histological examination and quantitative analysis of geno-
types determined increased p-α-synuclein staining as LBL
in the ipsilateral motor cortex of Tga20 mice compared to
Prnp 0 / 0 and Prnp+ /+ (Prnp 0 / 0 = 11 .86 ± 0 .91 ;
Prnp+/+ = 19.80 ± 2.25; Tga20 = 27.56 ± 2.19
(mean ± SEM). Prnp0/0 vs Prnp+/+, mean diff −7.94,
t = 2.669, 95% CI of diff = −15.63 to −0.2592. Prnp0/0 vs
Tga20, mean diff −15.70, t = 5.159, 95% CI of diff = −23.56
to −7.84. Prnp+/+ vs Tga20, mean diff −7.756, t = 2.795, 95%
CI of diff = −14.92 to −0.59; ANOVA Bonferroni multiple
comparison test) (Fig. 2). These data strongly suggest that
although non-mandatory, Prnp overexpression enhances the
regional transport of p-α-synuclein pathology in living mice.
Development of Microfluidic Devices to Monitor α-
Synuclein Fibril Transport α-Synuclein intracellular trans-
port has been studied in vitro using commercial microfluidic
devices (e.g. [45–48]). Our laboratory has developed two
microfluidic designs based on previously published devices
of our group (Fig. 3) [43]. Two different types of micro-
grooves (both 1 mm length) were generated for this study:
100 microgrooves of 3 μm (high) × 10 μm (wide) sections
and 100 microgrooves of 10 (high) × 10 μm (wide) sections
(Fig. 3a). Results in protein transport were similar for the two
devices since microfluidic pressures were controlled to avoid
non-specific non-neuronal transport (see below). As noted, α-
synuclein transport in vitro can be done both anterogradely
and retrogradely [45–47]. Thus, we cultured Prnp+/+ embry-
onic (E15.5) cortical neurons for 5–7 days in our devices to
ensure crossing of axons between A and B. Under these con-
ditions, around ≈85% of the devices showed large numbers of
crossing axons after Fluo4-AM staining between reservoirs
(Supplementary Fig. 2a, b). In addition, immunohistochemi-
cal analysis demonstrated that a large number of TUJ1-
positive neurons with fewer astrocytes (glial fibrillary acidic
protein (GFAP)-positive) and oligodendrocytes (olig2-
positive) were observed in the devices (Fig. 3b, c).
Recombinant (1 μg/ml) mouse (Fig. 3) or human
(Supplementary Fig. 3) α-synuclein fibrils were added to
one of the reservoirs (mainly in A; (A *) in Fig. 3) following
the protocol of [46] with different volumes of medium be-
tween reservoirs (B > A; 100 μl), and their transport
(A ⇒ B) were analysed 5 days later with immunocytochemis-
try (Fig. 3d–h, Supplementary Fig. 3) or western blot (Fig. 3i
and Supplementary Figs. 2 and 4).
Fig. 2 Increased α-synuclein labelling as LBL aggregates in the
neocortex in Tga20 mice. a–c Examples of p-α-synuclein aggregates in
the motor cortex of Prnp0/0, Prnp+/+ and Tga20mice injected with mouse
α-synuclein fibrils in the postcommissural striatum. Note the relevant
accumulation of p-α-synuclein labelling in intracellular deposits of
retrograde-labelled neurons in the cortical layer V of Tga20 mice. The
LBL and LNL aggregates can be clearly seen over the pale background in
the cortex. d Graph illustrating the quantification of the neuronal
aggregates in the different genotypes. Each count represents one
section. (Mice number Prnp+/+ (n = 5); Prnp0/0 (n = 4) and Tga20
(n = 6)). In addition, the mean ± SEM is also plotted. *P < 0.05 and
***P < 0.01, ANOVA Bonferroni post hoc test. Scale bar: a = 100 μm
pertains to b and c
Fig. 3 Analysis of α-synuclein transport using microfluidic devices. a
2D representation of the two PDMS devices used in the present study. b, c
Double immunofluorescence photomicrographs illustrating TUJ1/GFAP
(b) or TUJ1/olig2 (c) staining in primary cultured neurons in the devices.
d Primary cortical cultures of the Prnp+/+ were maintained in the devices
for 7 days. Then, mouse α-synuclein fibrils were added to A reservoir
(asterisk), and their transport to B reservoir was analysed with
immunocytochemistry (d–h) and western blot (i). d Examples of
double-labelled neurons (TUJ1/α-synuclein) in B reservoir (indicated
with camera icon) showing α-synuclein labelling (arrows). e, f
Examples of p-α-synuclein-labelled neurons and neurites (arrows) in A
reservoir (indicated with camera icon). g, h Examples of p-α-synuclein-
labelled neurons and axons (arrows) in B reservoir (indicated with
camera icon). i Western blot showing the presence of α-synuclein
(17 kDa band) in both cellular extracts (A and B) and the absence in
the culture medium of B in contrast to A reservoir, avoiding passive
fluid transport. Membranes were reblotted with an antibody against β-
tubulin or TUJ1 for standardization and characterization. Scale bar: b, d,
e, g and h = 40 μm
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First, we aimed to determine endogenous α-synuclein and
p-α-synuclein labelling in our devices. At these stages, a very
low α-synuclein immunostaining was observed in untreated
devices in both A and B reservoirs. In addition, after using the
p-α-synuclein (p129S/81A) antibody, no labelling was
observed in the absence of α-synuclein fibril cultures.
However, after α-synuclein fibril treatment in A (Fig. 3d),
immunoreacted cultures showed the presence of relevant α-
synuclein staining in the perikaryon, neurites and axons of
cultured TUJ1-positive neurons in B (Fig. 3d). In addition,
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relevant p-α-synuclein labelling was observed in morpholog-
ically identified neurons located in both reservoirs (A and B)
(Fig. 3e–h). More relevantly, p-α-synuclein aggregates (after
mouse or human fibril treatment) were detected in identified
axons and in the cytoplasm of cultured neurons in A as well in
B (Fig. 3e–h, Supplementary Fig. 3b–g). In addition, to avoid
the presence of passive transport of α-synuclein, we devel-
oped the detection of the protein in cell extracts and media
of both reservoirs using the QuantaRed™-enhanced
chemifluorescent HRP substrate (Thermo Fisher, cat. 15159)
(Fig. 3i and Supplementary Figs. 2 and 4). After mouse α-
synuclein fibril incubation in A, results revealed the presence
of α-synuclein in both cellular extracts (A and B), with the
absence in the culture media of B in contrast to the media of A
reservoir, indicating the absence of passive fluidic flux be-
tween A ⇒ B (Fig. 3i and Supplementary Figs. 2 and 4) [43,
46]. In our devices, although different α-synuclein bands
could be detected in A, the low molecular weight of α-
synuclein (≈17 kDa) was mainly detected in B, as also recent-
ly reported by [47](Fig. 3, Supplementary Figs. 2 and 4). α-
Synuclein transport was always observed in those devices
showing large connectivity between A and B reservoirs
(Fig. 3, Supplementary Figs. 3 and 4). However, in those
displaying few axon numbers crossing between reservoirs
(Supplementary Fig. 3), α-synuclein was almost absent in B
(cell and media) and was only detected in the cellular and
media extracts of A. This reinforced the notion of a specific
axonal transport of α-synuclein fibrils between neurons
displaying low endogenous levels ofα-synuclein at these time
points in culture (Supplementary Fig. 2). Thus, these devices
are well suited to monitor cellular transport of mouse or hu-
man α-synuclein fibrils.
In Vitro Transport of α-Synuclein under Prnp Dosage As
indicated above, PrPC has been described as a receptor for β-
amyloid [4, 49]. Although the participation of PrPC in the
intercellular β-amyloid transport in microfluidic devices re-
mains elusive, its expression seems to be needed to trigger β-
amyloid-mediated effects in treated neurons (see the
BIntroduction^ section for references). Primary cortical cul-
tures from Prnp+/+, Prnp0/0 and Tga20 embryos were treated
with exogenous recombinant mouse α-synuclein fibrils, and
both the binding in treated cells and their transport was
analysed with western blot or immunocytochemistry
(Fig. 4). First, we checked the percentage of devices without
the α-synuclein transport. Results indicated that 14.28%
(Prnp0/0), 22.22% (Prnp+/+) and 16.66% (Tga20) of the cul-
tures showed no α-synuclein transport in our microfluidic
devices. In fact, these cultures displayed very few axons cross-
ing between reservoirs as determined by Fluo4-AM staining
(see example in Supplementary Fig. 2a). Second, we analysed
the presence of exogenous α-synuclein in neurons in B reser-
voir after treatment in A. We were able to determine the
presence of α-synuclein in neurons, irrespective of the Prnp
genotype (Fig. 4a–d). Since neuronal presence of α-synuclein
fibrils cannot be ascertained in a quantitative basis by simple
fluorescence analysis, we processed parallel samples for west-
ern blot. Indeed, after protofibril treatment in A, western blots
revealed increased α-synuclein/tubulin ratio in Tga20 than in
WT and Prnp0/0 cultured neurons in A suggesting a tendency
of higher protofibril binding in presence of larger PrPC
amounts (Prnp0/0 = 0.344 ± 0.07; Prnp+/+ = 0.386 ± 0.08,
Tga20 = 0.56 ± 0.14 (mean ± SEM)) (Fig. 4b). Next, western
blot results corroborated thatα-synuclein protofibrils could be
transported to neurons from A to B irrespective of the Prnp
genotype (Fig. 4). However, although not statistically signifi-
cant (ANOVA Bonferroni post hoc test), values for
transported α-synuclein were slightly higher in Tga20-
derived primary neuronal cultures as compared to wild-type
and Prnp0 / 0 (Fig . 4c) (Prnp0 / 0 = 0.467 ± 0.09;
Prnp+/+ = 0.5561 ± 0.106, Tga20 = 0.7801 ± 0.206
(mean ± SEM)).
Increased Binding of α-Synuclein in Prnp-Transfected
Cells Various possibilities have been proposed regarding
α-synuclein interaction with plasma membrane [50–52,
48]. Thus, due to the in vitro and in vivo observations,
we aimed to determine whether PrPC overexpression en-
hanced α-synuclein interaction with cells (Figs. 5 and 6
and Supplementary Fig. 5). We increased PrPC expression
in a cellular system with very low PrPC expression, low
endogenous α-synuclein binding properties [48] and lack
of expression of other α-synuclein binding proteins
(LAG3, neurexin 1β or APLP1) (HEK293 cells, Fig. 5)
to analyse the binding of α-synuclein mouse protofibrils.
First, HEK293 cells were transfected with PrPC-IRES-
GFP, incubated with sonicated mouse α-synuclein
protofibrils (1 μg/ml) and processed for α-synuclein
immunolabelling (Fig. 5b). Results revealed that most
GFP-positive HEK203 cells were labelled with the α-
synuclein antibody (Fig. 5b). In a second set of experi-
ments, HEK293 cells were transfected either with full-
length Prnp (pcDNA-Prnp) or mock (pcDNA) plasmids
and then incubated 24 h later with mouse α-synuclein
fibrils; their cellular binding was analysed using western
blot and immunocytochemistry for PrPC and α-synuclein
(Fig. 5a, c–h). Blots indicated the presence of the 17 kDa
α-synuclein band only in protein extracts of Prnp-
transfected cells after α-synuclein treatment (Fig. 5a).
This increased binding was also corroborated by immuno-
cytochemistry in which α-synuclein labelling was promi-
nent in identified double-labelled Prnp-expressing cells in
contrast to non-expressing HEK293 cells (Fig. 5c–h).
Fluorescence microscopy observation developed in 314
(PrPC-positive) identified cells from three different exper-
iments demonstrated that 91.08% of the analysed cells
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with relevant α-synuclein labelling were also positive for
PrPC (Fig. 5c, d). In contrast, a discrete puncta-like label-
ling of α-synuclein was observed randomly distributed
over mock-transfected HEK293 cells with negligible
levels of PrPC (Fig. 5e). At high magnification, although
not exclusive, we determined a strong co-localization of
the α-synuclein and PrPC labelling in discrete membrane
regions of transfected cells, suggesting relevant cellular
binding of protofibrils in regions with high PrPC presence
(Fig. 5f–h).
Involvement of the ChargedCluster Domain of PrPC inα-
Synuclein Binding It has been described how the residues of
the CC of PrPC are involved in binding β-amyloid with PrPC
[53]. Hence, we aimed to determine whether this domain also
participates in α-synuclein binding (Fig. 6). After cloning, the
Fig. 4 Determination of α-synuclein transport in neuronal cultures from
mouse embryos carrying differing Prnp dosages. Recombinant mouse α-
synuclein protofibrils were added to A reservoir (asterisk), and its binding
to neurons in A reservoir as well as their transport towards B were
analysed by western blot in cellular extracts. a–d Examples of double-
labelled Prnp0/0 (a, b) and Prnp+/+ (c, d) neurons (TUJ1/α-synuclein) in
B reservoir showing discrete cytoplasmatic α-synuclein labelling
(arrows). e Examples of western blot determination of one device for
each Prnp genotype for α-synuclein. Anti-β-tubulin and anti-PrPC
monoclonal antibodies were used for standardization and genotype
characterization. Notice that PrPC was present in WT and Tga20 cells at
the time of treatment. PrPC is downregulated shortly after plating neurons,
and their levels increased over time in culture (see also [68] for details). f–
g Densitometric analysis (see the BMaterial and Methods^ section for
details) were performed, and quantification was represented as the ratio
between α-synuclein/β-tubulin detected in A reservoir after protofibril
treatment (b) and ratio between α-synuclein/β-tubulin detected in B vs A
reservoirs (c). Results for each device are represented by a single plot in
the scatter plot. In addition, mean ± SEM is also plotted
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expression of all PrPC variants in HEK293 cells were tested by
western blotting (Supplementary Fig. 5). The endogenous lev-
el of Prnp expression in HEK293 was low (Fig. 5a), and all
PrPC-modified proteins were detectable (Supplementary
Fig. 5). However, expression of ΔF35 was markedly lower
than that of the rest of the deleted forms, representing less than
50% of the expression of full-length PrPC (Supplementary
Fig. 5). At this point, we considered the fact that some of these
constructs are able to induce cell death when overexpressed in
cell lines [54, 1]. Results indicate that only ΔF35 increased
caspase 3 activity in transfected cells in contrast to other PrPC
constructs (relative fluorescence units (RFU) ΔF35/
pcDNA = 2.15 ± 0.38; ΔCC/pcDNA = 0.92 ± 0.27; ΔHR/
pcDNA = 1.11 ± 0.21; PrPC/pcDNA = 1.14 ± 0.09;
mean ± SEM) (Supplementary Fig. 5). After these results,
we ignored ΔF35 in the next experiments and focused on
the central domain (ΔCC and ΔHR) of PrPC (Figs. 5 and
6). In the experiments, we reduced the amount of the cDNA
to half during cell transfection to ensure clear immunocyto-
chemical detection of transfected cells. After transfection and
Fig. 5 Increased binding of α-synuclein in Prnp-transfected HEK293
cells. a Western blot shows increased labelling of the 17 KDa α-
synuclein band in HEK293 cells transfected with mouse Prnp-encoding
plasmid in contrast to mock-transfected cells. Anti-β-tubulin monoclonal
antibody was used for standardization, and anti-PrPC antibody was used
to check PrPC overexpression after transfection. Notice that HEK293
cells showed a very low endogenous PrPC expression. The upper bands
observed after protofibril treatment corresponded to non-monomeric
forms of α-synuclein. b Examples of double-labelled GFP/α-synuclein
HEK293 cells after transfection of PrPC-IRES-GFP. Note the presence of
the relevant labelling in the two transfected cells in comparison to the
disperse α-synuclein labelling in non-transfected cells (arrows). c–e
Fluorescence photomicrographs showing examples of double-labelled
cells PrPC (d) overexpressing cells and α-synuclein (c). HEK293 cells
were transfected with Prnp-encoding plasmid (c, d) or mock-transfected
cells (e). Arrows in c and d point to double-labelled cells, and the asterisk
in d labels a PrPC-positive/α-synuclein-negative HEK293 cell. Arrows in
e point to α-synuclein labelling in mock-transfected cells. f–h High
magnification photomicrograph illustrating the distribution of α-
synuclein (f) in PrPC-transfected HEK293 cells (g). Notice the relevant
colocalization in several domains of the transfected cell including the
plasma membrane (arrows in g and h). Scale bars: b, e = 25 μm. c,
f = 25 μm belongs to d; g and h, respectively
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immunocytochemistry, only 5.83% (22 of 377, n = 3) of the
ΔCC-labelled cells were α-synuclein-positive (Fig. 6d–g) in
contrast to ΔHR/α-synuclein (96.49% (110 of 114, n = 3))
(Fig. 6h–k) and PrPC/α-synuclein (91.08% (286 of 314 cells,
n = 3) (Fig. 5c–h and Fig. 6b, c), indicating the participation of
the CC domain of PrPC in α-synuclein binding to PrPC-
transfected HEK293 cells.
Discussion
In this study, we determined that α-synuclein fibrils can be
transported to different brain regions of wild-type mice after
injection in the postcommissural striatum. Our results rein-
force the notion that the spreading of p-α-synuclein pathology
does not occur by diffusion or non-specific transport [45]. The
transport observed in our experiments was similar to that re-
ported in other studies using wild-type mice [29, 28], with
relevant p-α-synuclein deposits in the striatum, substantia
nigra, amygdala and neocortex. The anatomical connections
between the striatum, substantia nigra, amygdala and neocor-
tex are well described in the literature (e.g. [55]) and support
the observed transport of α-synuclein. Although it has been
reported to exist anterograde and retrograde transport of α-
synuclein (see above), in our experiments, transported α-
synuclein seemed to be more often transported retrogradely
in the brain parenchyma, as suggested in other works [29, 28].
Our results also demonstrate for the first time that p-α-
synuclein pathology after injection could spread to different
brain regions in the absence of PrPC. Thus, Prnp expression is
not mandatory for α-synuclein transport in the mouse brain,
although increased levels of α-synuclein transport can be seen
in wild-type and overexpressing mice. In fact, it has been
reported that the absence of PrPC does not modify the appear-
ance or temporal evolution of p-α-synuclein deposits in trans-
genic mice overexpressing human α-synuclein driven by a
platelet-derived growth factor-β promoter [56]. Furthermore,
changes on Prnp dosage do not alter α-synuclein expression
in adult mice (not shown). Although data using additional
models of synucleinopathies (e.g. A53T mice) have not been
published, the present results are in line with these observa-
tions [56]. However, we also determined an increased number
of motor pyramidal neurons displaying LBL aggregates in
Prnp-overexpressing mice which suggest that, as also
Fig. 6 a Scheme of theΔCC, ΔHR maps and the full-length PrPC. b, c
Fluorescence photomicrographs showing examples of double-labelled
PrPC/α-synuclein cells (arrows). d, e Fluorescence photomicrographs
showing examples of double-labelled cultures using the 6H4 PrPC and
α-synuclein antibodies. Note the absence of double-labelled cells in these
examples (arrows) and the background staining of α-synuclein labelling
in non-transfected cells. h–k Fluorescence photomicrographs showing
examples of double-labelled ΔHR/α-synuclein cells (arrows) after
treatment over the labelling of non-transfected cells. Scale bar: b, d, f,
h and j = 40 μm pertains to c and e, respectively
Mol Neurobiol
reported for β-amyloid, PrPC might participate in the cellular
binding of α-synuclein and its expansion.
The interaction of several amyloids to PrPC is well charac-
terized [14, 6, 4, 15–17]. We determined, using two different
Prnp constructs, that their overexpression can enhance the
binding ofα-synuclein in HEK293 cells with low endogenous
capability of α-synuclein binding (see also [48] for details).
Several studies have reported the interaction of endogenous
peptides of the amyloid family with the plasma membrane
[57–61]. In fact, the interaction of Aβ, human or rat amylin,
PrP(106–126) or α-synuclein fibrils with plasma membrane has
been well described [57–60, 62], and several putative interac-
tions with plasma membrane proteins have been described as
well (e.g. APP [59] or GRP78 [51]). To this concern, a recent
study of Mao and coworkers [48] reviewed in [63] points to
the lymphocyte-activation gene 3 (LAG3/CD223) as the neu-
ronal receptor of α-synuclein. LAG3 showed increased bind-
ing properties to α-synuclein protofibrils as compared to
neurexin 1β, and APLP1 in SH-SY5Y-overexpressing cells
[48]. mRNA levels of LAG3 do not change between Prnp
genotypes (GEO database ref. GSE16223). However, and
since a functional interaction between LAG3 with PrPC can-
not be ruled out, we hypothesise that PrPC as well as other
proteins (e.g. GRP78) may cooperate with LAG3 in neuronal
α-synuclein transport. This is also relevant if considered that
the absence of LAG3 does not fully impair α-synuclein
protofibril transport in vitro and in vivo [48].
Although not described for other fibrillar peptides, PrPC
has been reported as a receptor for Aβ (see above). The pres-
ent study indicates that PrPC might contribute to enhanced
binding of α-synuclein fibrils to the plasma membrane, in line
with other studies, reporting an increased level of binding
between Aβ and PrPC during ageing in several mouse models
of Alzheimer’s disease [15]. In addition, our data suggest that
the CC domain actively participates in α-synuclein binding.
Residues located in the CC domain (aa 90–110 or aa 91–115)
have been involved in binding with β-amyloid [64, 53] in
cooperation with the N-terminal residues 23–58 [53]. As these
PrPC domains have been revealed as putative pharmacological
targets for Alzheimer’s disease [65–67], our data might also
enhance the eligibility of PrPC as a putative target to modulate
α-synuclein expansion.
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